Literature DB >> 9833015

Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test.

F Sams-Dodd1.   

Abstract

Phencyclidine (PCP) induces stereotyped behaviour and social isolation in rats; comparisons with clinical observations have suggested that these behaviours may mimic certain aspects of the positive and the negative symptoms, respectively, of an acute schizophrenic episode. Novel antipsychotics are effective in treating the positive symptoms in schizophrenic patients and have also shown some promise in treating the negative symptoms. In the present study the effects of the novel antipsychotics remoxipride (2.5-20 mg/kg), risperidone (0.02-0.63 mg/kg), sertindole (0.01-2.5 mg/kg), olanzapine (0.16-2.5 mg/kg) and quetiapine (0.16-10 mg/kg) on PCP-induced behaviours were determined. The drugs were administered daily for 3 or 21 days in combination with vehicle or 2.0 mg/kg of PCP for the last 3 days of the administration regime, and the rats were tested using the social interaction test. The antipsychotic drugs all reliably reduced the level of PCP-induced stereotyped behaviour and had distinct effects on PCP-induced social isolation. Comparison with clinical findings suggests that the PCP-induced behaviours respond to treatment with antipsychotic drugs in a manner that correlates well with clinical observations, and that this animal model of schizophrenia may be useful for evaluating novel drug candidates. However, the study also showed that additional experiments are required to determine the specificity by which antipsychotic drugs alleviate PCP-induced behaviours because most of the drugs also affected considerably the behaviour of the control animals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9833015

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  21 in total

1.  Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway.

Authors:  Ornella Valenti; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176

2.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

3.  Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory.

Authors:  U Schroeder; H Schroeder; H Schwegler; B A Sabel
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 4.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.

Authors:  Anna Sławińska; Joanna M Wierońska; Katarzyna Stachowicz; Marcin Marciniak; Magdalena Lasoń-Tyburkiewicz; Piotr Gruca; Mariusz Papp; Magdalena Kusek; Krzysztof Tokarski; Darío Doller; Andrzej Pilc
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

6.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

7.  Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine.

Authors:  W Michael Bullock; Federico Bolognani; Paolo Botta; C Fernando Valenzuela; Nora I Perrone-Bizzozero
Journal:  Neurochem Int       Date:  2009-08-03       Impact factor: 3.921

8.  The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression.

Authors:  Laura Jiménez-Sánchez; Leticia Campa; Yves P Auberson; Albert Adell
Journal:  Neuropsychopharmacology       Date:  2014-05-29       Impact factor: 7.853

Review 9.  Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.

Authors:  Christina A Wilson; James I Koenig
Journal:  Eur Neuropsychopharmacol       Date:  2013-11-26       Impact factor: 4.600

Review 10.  Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Authors:  Seong S Shim; Michael D Hammonds; Baik S Kee
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.